ReShape Lifesciences Inc. (RSLS)
0.31
-0.05 (-14.62%)
At close: Apr 17, 2025, 3:59 PM
0.31
-1.58%
After-hours: Apr 17, 2025, 06:05 PM EDT
ReShape Lifesciences Revenue Breakdown
| Period Ending | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|
| Product And Service Other Revenue | 14.29K | 19.82K | 8.57K |
| Product And Service Other Revenue Growth | -27.90% | +131.29% | n/a |
| Product Revenue | 335.95K | 633.55K | 941.43K |
| Product Revenue Growth | -46.97% | -32.70% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Australia Revenue | 526K | 688K | 1.04M | 1.82M |
| Australia Revenue Growth | -23.55% | -33.78% | -43.04% | n/a |
| Europe Revenue | 956K | 1.25M | 2.13M | n/a |
| Europe Revenue Growth | -23.64% | -41.14% | n/a | n/a |
| Rest Of World Revenue | 62K | 70K | 137K | n/a |
| Rest Of World Revenue Growth | -11.43% | -48.91% | n/a | n/a |
| United States Revenue | 7.13M | 9.23M | 10.3M | n/a |
| United States Revenue Growth | -22.71% | -10.36% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.8M | 2.79M | 2.89M | 3M | 3.85M | 4.62M | 6.4M | 5.87M | 6.39M | 10M | 8.87M | 8.3M | 15.55M | 5.75M | 3.97M | 3.97M | 3.59M | 3.37M | 4.29M | 4.5M | 5.36M | 6.79M | 5.42M | -3.87M | 6.38M | 6.71M | 10.05M | 9.9M | 4.6M | 5.56M | 5.93M | 2.89M | 3.36M | 5.59M | 6.14M | 5.94M | 4.29M | 4.94M | 4.73M |
| Selling, General, and Administrative Revenue Growth | +0.43% | -3.53% | -3.57% | -22.11% | -16.72% | -27.80% | +9.16% | -8.20% | -36.10% | +12.73% | +6.82% | -46.59% | +170.31% | +44.89% | +0.08% | +10.38% | +6.65% | -21.45% | -4.58% | -16.15% | -21.05% | +25.29% | -239.99% | -160.72% | -4.95% | -33.21% | +1.50% | +115.39% | -17.36% | -6.21% | +104.93% | -13.93% | -39.82% | -9.05% | +3.39% | +38.49% | -13.11% | +4.43% | n/a |
| Research and Development Revenue | 399K | 399K | 484K | 739K | 542K | 581K | 453K | 441K | 583K | 747K | 748K | 277K | 1.57M | 103K | 571K | 879K | 859K | 465K | 1.29M | 247K | 858K | 960K | 1.06M | -656.98K | 1.25M | 2.44M | 2.69M | 2.19M | 1.11M | 1.35M | 1.12M | 1.29M | 1.25M | 1.19M | 1.43M | 1.69M | 1.76M | 2.45M | 2.24M |
| Research and Development Revenue Growth | 0.00% | -17.56% | -34.51% | +36.35% | -6.71% | +28.26% | +2.72% | -24.36% | -21.95% | -0.13% | +170.04% | -82.37% | +1425.24% | -81.96% | -35.04% | +2.33% | +84.73% | -64.09% | +424.29% | -71.21% | -10.62% | -9.09% | -260.74% | -152.46% | -48.66% | -9.24% | +22.78% | +97.27% | -17.93% | +20.25% | -12.83% | +2.91% | +5.01% | -16.67% | -15.24% | -4.09% | -28.16% | +9.65% | n/a |
| Sales and Marketing Revenue | 719K | 670K | 1.02M | 1.4M | 1.79M | 2.18M | 2.18M | 2.1M | 2.6M | 4.64M | 4.71M | 2.98M | 3.5M | 1.44M | 1.25M | 1.25M | 1.16M | 831K | 1.45M | 4.85M | 950K | 1.27M | 1.12M | 5.24M | 2.09M | 2.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +7.31% | -34.25% | -27.11% | -21.94% | -17.73% | -0.23% | +3.76% | -19.27% | -43.81% | -1.51% | +58.01% | -14.79% | +142.61% | +15.28% | +0.08% | +7.67% | +39.59% | -42.85% | -70.00% | +410.21% | -25.26% | +13.79% | -78.67% | +150.57% | -12.31% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |